The healthcare and life sciences landscape has reached a structural inflection point in 2026, transitioning from a period of speculative artificial intelligence experimentation to one of enterprise-wide production and deep-tissue integration. This shift is catalysed by a convergence of unsustainable macroeconomic pressures: rising healthcare expenditures—now consuming 18% of Gross Domestic Product (GDP) in the United States and 12% in Germany—workforce shortages, and a declin